大豆黄素衍生物LRXH609 的减肥作用及机理探讨

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (5): 519-523.

大豆黄素衍生物LRXH609 的减肥作用及机理探讨

巫冠中, 郭永起, 苏欣, 杨红霞, 章娟

中国药科大学药理教研室, 南京210009, 江苏

收稿日期:2009-04-11 修回日期:2009-05-14 发布日期:2020-11-09
作者简介:巫冠中, 男, 副教授, 研究方向为内分泌药理学。Tel:025-80287023 E-mail:zhonghuw @sohu. com

Studies on the antiobesity action and mechanisms of daidzein derivative:LRXH609

WU Guan-zhong, GUO Yong-qi, SU Xin, YANG Hong-xia, ZHANG Jian

Department of Pharmacology, China Pharmaceutical University, Nanjing 210009, Jiangsu, China

Received:2009-04-11 Revised:2009-05-14 Published:2020-11-09

摘要/Abstract

摘要： 目的:探讨大豆黄素衍生物LRXH609(LRX) 的减肥作用和可能的机理。方法:以高脂饮食诱导肥胖大鼠, 测量体重、Lee′s 指数、腹腔脂肪重量、摄食量、血脂和血糖, 检验LRX 灌服30 d后的减肥效果;体外培养诱导分化3T3-L1 前脂肪细胞, 观察药物对脂肪细胞增殖、脂质合成和分解的影响。结果:LRX 显著降低高脂饮食诱导的肥胖大鼠体重、Lee′s 指数、腹腔脂肪重量;降低血液中TC 和游离脂肪酸(FFA) 含量;抑制3T3-L1 前脂肪细胞增殖;显著提高3T3-L1 前脂肪细胞内激素敏感脂酶(HSL) 活性, 促进脂肪分解释放甘油(Gly), 减少细胞内TG 含量。结论:LRXH609 有显著的减肥和调血脂作用, 可能的机理是通过抑制前脂肪细胞增殖和分化, 激活HSL 促进脂肪细胞内TG 分解, 降低脂肪细胞内TG 存储量。

关键词: 肥胖, 大豆黄素, 3T3-L1 细胞, 激素敏感脂酶

Abstract: AIM:To approach the antiobesity action and mechanisms of the daidzein derivative: LRXH609 (LRX). METHODS:The body weight, Lee′s index, total weight of celiac fat tissue, food intake, serum glucose and lipids in obese rats induced by a high-fat diet were measured and the antiobesity action was tested after LRX was administered for 30 days. 3T3-L1 pre-adipocytes were induced by in vitro culture, the effects of LRX on cell proliferation, lipogenesis, lipolysis were observed. RESULTS:The body weight, Lee′s index, fat tissue weight in obese rats were significantly decreased by LRX, and the concentrations of TC, FFA in serum were decreased, the proliferation of 3T3-L1 pre-adipocytes was inhibited, the activities of hormone sensitive lipase in 3T3-L1 pre-adipocytes were significantly elevated, the glycerine release from adipocytes was promoted and the concentrations of TG in adipocytes were decreased. CONCLUSION: LRX plays a role in antiobesity action and regulating blood lipid and the mechanism might be related to inhibiting proliferation and differentiation of pre-adipocytes, stimulating TG decomposition by activating hormone-sensitive lipase and decreasing the TG storage in adipocyte.

Key words: obesity, daidzein, 3T3-L1 pre-adipocyte, hormone-sensitive lipase

中图分类号:

R965. 2

巫冠中, 郭永起, 苏欣, 杨红霞, 章娟. 大豆黄素衍生物LRXH609 的减肥作用及机理探讨[J]. 中国临床药理学与治疗学, 2009, 14(5): 519-523.

WU Guan-zhong, GUO Yong-qi, SU Xin, YANG Hong-xia, ZHANG Jian. Studies on the antiobesity action and mechanisms of daidzein derivative:LRXH609[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(5): 519-523.

参考文献

[1] Rimbach G, Boesch-Saadatmandi C, Frank J. Dietary isoflavones in the prevention of cardiovascular disease-A molecular perspective[J]. Food Chem Toxicol, 2008, 46 (4): 1308-1319.
[2] Marla SJ, Manzoni MSc, Elizeu A, et al.Fermented soy product supplemented with isoflavones affected fat depots in juvenile rats[J]. Nutrition, 2005, 21 (10): 1018- 1024.
[3] Naaz A, Yellayi S, Zakroczymski MA, et al. The soy isoflavone genistein decreases adipose deposition in mice[J]. Endocrinology, 2003, 144(8): 3315-3320.
[4] 孙志, 张中成, 刘志城.营养性肥胖动物模型的实验研究[J]. 中国药理学通报, 2002, 18(4): 466-467.
[5] Yang JY, Della-Fera MA, Baile CA.Guggulsterone inhibits adipocyte differentiation and induces apoptosis in 3T3-L1 Cells[J]. Obesity, 2008, 16(1): 16-22.
[6] Moreno DA, Ilic N, Poulev A.Effects of Arachis hypogaeanutshell extract on lipid metabolic enzymes and obesity parameters[J]. Life Sci, 2006, 78(24): 2797- 2803.
[7] Ahn J, Lee H, Kim S, et al. The anti-obesity effect of quercetin is mediated by the AMPK andMAPK signaling pathways[J]. Biochem Biophys Res Commun, 2008, 373 (4): 545-549.
[8] Moon HS, Lee HG, Choi YJ, et al. Proposed mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity [J]. Chem Biol Interact, 2007, 167(2): 85-98.
[9] Haemmerle G, Zimmermann R, Zechner R.Letting lipids go: hormone-sensitive lipase [J]. Curr Opin Lipidol, 2003, 14(3): 289-297.
[10] Langin D.Adipose tissue lipolysis as a metabolie pathway to define pharmacological strategies against obesity and the metabolic syndrome[J]. Pharmaeol Res, 2006, 53 (6): 482-491.
[11] Hodsona L, Skeaff CM, Fielding BA.Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake[J]. Prog Lipid Res, 2008, 47 (5): 348-380.

[1]	郭怡洵, 关晓印, 王博, 魏英达, 张岩, 林建华. 肌少性肥胖的发病机制及潜在治疗靶点研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 341-346.
[2]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[3]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[4]	孔祥, 华强, 姚新明, 孟祥健, 钟民, 郭莉群. 芝麻酚调控巨噬细胞极化改善肥胖小鼠脂肪组织炎症及胰岛素抵抗[J]. 中国临床药理学与治疗学, 2020, 25(7): 728-733.
[5]	袁李佳龙，秦旭平. ATP合酶β亚基功能与疾病[J]. 中国临床药理学与治疗学, 2018, 23(4): 464-470.
[6]	曾慧，肖兰，易宏辉. HRH1与HRH2受体基因多态性与肥胖以及肥胖相关性状的关联分析[J]. 中国临床药理学与治疗学, 2016, 21(9): 1028-1032.
[7]	黄昭穗，杨骄，黄昭瑄，栾丽丽，王赐玉，杨红英. 利拉鲁肽在血糖控制不佳的T2MD伴肥胖患者中临床疗效观察[J]. 中国临床药理学与治疗学, 2016, 21(1): 87-92.
[8]	沈纪中, 柳航. 高糖饮水诱导代谢综合征小鼠模型的实验研究[J]. 中国临床药理学与治疗学, 2014, 19(9): 1011-1015.
[9]	陈咨苗, 王美荣, 叶婷婷, 顾雪疆, 陈雄, 朱虹, 倪连松. 酮替芬对高糖高脂饮食诱导肥胖模型大鼠的减肥作用[J]. 中国临床药理学与治疗学, 2014, 19(1): 23-28.
[10]	刘靖, 孙宁玲, 杨松娜, 马志毅, 杨靓. 奥利司他对肥胖高血压患者非内皮依赖性血管舒张功能的影响[J]. 中国临床药理学与治疗学, 2009, 14(9): 1061-1064.
[11]	崔明霞, 王磊, 张宝来, 路莉, 王莉, 郑荣梁, 吴勇杰. 糖尿病性肥胖大鼠模型的建立及西布曲明对其治疗作用的研究[J]. 中国临床药理学与治疗学, 2008, 13(12): 1325-1329.
[12]	庞小翼, 董志, 傅洁民. 大麻素受体1阻断剂在治疗肥胖症中的作用[J]. 中国临床药理学与治疗学, 2006, 11(6): 606-609.
[13]	陈光亮, 李莉, 严尚学, 黄德武. 盐酸西布曲明对营养性肥胖大鼠的减肥作用[J]. 中国临床药理学与治疗学, 2003, 8(1): 55-58.
[14]	王绘, 陈斌. 西布曲明对不同肥胖者的减重作用[J]. 中国临床药理学与治疗学, 2002, 7(4): 327-330.
[15]	王平芳, 杨雅, 廖二元, 颜湘, 张红, 何凌, 朱旭平. 西布曲明对肥胖伴糖脂代谢异常的治疗作用[J]. 中国临床药理学与治疗学, 2002, 7(3): 224-230.